Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Mayo Clinic
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
University of Pisa
Servier
Brigham and Women's Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
The First Affiliated Hospital of Xiamen University
National Taiwan University Hospital
M.D. Anderson Cancer Center
Stanford University
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Eli Lilly and Company
Taichung Veterans General Hospital
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
Instituto do Cancer do Estado de São Paulo
Radboud University Medical Center
National Institutes of Health Clinical Center (CC)
Bayer
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Taiwan University Hospital
National Taiwan University Hospital
Zhejiang Cancer Hospital
Alliance for Clinical Trials in Oncology
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
AstraZeneca
Ilsan Cha hospital
National Institutes of Health Clinical Center (CC)
Sotio Biotech Inc.
Pfizer
Pfizer
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Qianfoshan Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University